GILZ regulates type I interferon release and sequesters STAT1

Champa Nataraja, Jacqueline Flynn, Wendy Dankers, Melissa Northcott, Wendy Zhu, Rochelle Sherlock, Taylah J. Bennett, Brendan E. Russ, Iolanda Miceli, Mehnaz Pervin, Akshay D'Cruz, James Harris, Eric F. Morand, Sarah A. Jones

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


Glucocorticoids remain a mainstay of modern medicine due to their ability to broadly suppress immune activation. However, they cause severe adverse effects that warrant urgent development of a safer alternative. The glucocorticoid-induced leucine zipper (GILZ) gene, TSC22D3, is one of the most highly upregulated genes in response to glucocorticoid treatment, and reduced GILZ mRNA and protein levels are associated with increased severity of inflammation in systemic lupus erythematosus (SLE), Ulcerative Colitis, Psoriasis, and other autoimmune/autoinflammatory diseases. Here, we demonstrate that low GILZ permits expression of a type I interferon (IFN) signature, which is exacerbated in response to TLR7 and TLR9 stimulation. Conversely, overexpression of GILZ prevents IFN-stimulated gene (ISG) up-regulation in response to IFNα. Moreover, GILZ directly binds STAT1 and prevents its nuclear translocation, thereby negatively regulating IFN-induced gene expression and the auto-amplification loop of the IFN response. Thus, GILZ powerfully regulates both the expression and action of type I IFN, suggesting restoration of GILZ as an attractive therapeutic strategy for reducing reliance on glucocorticoids.

Original languageEnglish
Article number102858
Number of pages11
JournalJournal of Autoimmunity
Publication statusPublished - Jul 2022


  • Autoimmunity
  • GILZ
  • Glucocorticoids
  • Interferon
  • STAT1
  • Systemic lupus erythematosus

Cite this